Rodriguez-Wallberg Kenny A, Oktay Kutluk
Karolinska Institute, Department of Clinical Science, Intervention and Technology (CLINTEC), Division of Obstetrics and Gynecology, Stockholm, Sweden.
Clin Obstet Gynecol. 2010 Dec;53(4):753-62. doi: 10.1097/GRF.0b013e3181f96e00.
Fertility preservation is an important issue for young women diagnosed with breast cancer. The most well-established options for fertility preservation in cancer patients, embryo and oocyte cryopreservation, have not been traditionally offered to breast cancer patients as estradiol rise during standard stimulation protocols may not be safe for those patients. Potentially safer stimulation protocols using tamoxifen and aromatase inhibitors induce lower levels of estradiol whereas similar results in terms of number of oocyte and embryo obtained to standard protocols. Cryopreservation of immature oocytes and ovarian cortical tissue, both still experimental methods, are also fertility preservation options for breast cancer patients.
对于被诊断患有乳腺癌的年轻女性来说，生育力保存是一个重要问题。癌症患者生育力保存最成熟的方法，即胚胎和卵母细胞冷冻保存，传统上并未提供给乳腺癌患者，因为在标准刺激方案中雌二醇水平升高对这些患者可能不安全。使用他莫昔芬和芳香化酶抑制剂的潜在更安全刺激方案可诱导较低水平的雌二醇，而在获得的卵母细胞和胚胎数量方面与标准方案有相似结果。未成熟卵母细胞和卵巢皮质组织的冷冻保存，这两种方法仍处于实验阶段，也是乳腺癌患者的生育力保存选择。
